



Antengene to Host Webcast on Full Year 2022 Financial Results on Tuesday, March 28, 2023

Shanghai and Hong Kong, PRC, March 15, 2023 — Antengene Corporation Limited (“**Antengene**” SEHK: 6996.HK), a leading, commercial-stage, innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that **it will announce full-year 2022 financial results and review the results via webcasts on Tuesday, March 28, 2023.**

Details of the Webcasts

In Chinese

Date: Tuesday, March 28, 2023

Time: 5:00 – 6:00 PM (Beijing Time)

Webcast: <https://s.comein.cn/ANnm5>

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室

Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China

Tel: (86) 021 3250 1095

Fax: (86) 021 3250 1062

www.antengene.com



In English

Date: Tuesday, March 28, 2023

Time: 8:30 – 9:30 AM (Eastern Time)

8:30 – 9:30 PM (Beijing Time)

Registration Access:

https://goldmansachs.zoom.us/webinar/register/WN_h0tb7v77RR-QeUas7bz5mA

*Please pre-registration to access the webcast.

The conference call will be webcast live and a link to the webcast can be accessed through Antengene’s website at www.antengene.com in the “Investor Relations” section. To ensure a timely connection, **it is recommended that participants register at least 15 minutes prior to the scheduled webcast.** An archived webcast, as well as slides and audio webcast can also be accessed by visiting the “Investor Relations” section. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website for 30 days.

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室

Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China

Tel: (86) 021 3250 1095

Fax: (86) 021 3250 1062

www.antengene.com



About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “**Treating Patients Beyond Borders**”.

Since 2017, Antengene has built a broad and expanding pipeline of 13 clinical and preclinical assets, of which 10 are global rights assets, and 3 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 28 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO[®] (selinexor) already approved in Mainland of China, Taiwan, China, South Korea, Singapore and Australia.

Forward-looking statements

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室

Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China

Tel: (86) 021 3250 1095

Fax: (86) 021 3250 1062

www.antengene.com

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company’s Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.